At 2 years, the cardiac mortality rate was still lower than the study’s prespecified performance goal of 25% at 1 year, hemodynamics were excellent, rates of paravalvular leak were very low, and there were significant gains in quality of life. 

The release of these results indicates that JenaValve Trilogy™ is moving forward to benefit more patients! 

For more information, please refer to TCT2024 conference website: https://www.tctmd.com/news/align-ar-2-yearsshows-promise-tavi-trilogy-aortic-regurgitation